MCID: KHN001
MIFTS: 47

Kuhnt-Junius Degeneration

Categories: Eye diseases

Aliases & Classifications for Kuhnt-Junius Degeneration

MalaCards integrated aliases for Kuhnt-Junius Degeneration:

Name: Kuhnt-Junius Degeneration 12 15
Neovascular Age-Related Macular Degeneration 12 15
Susceptibility to Neovascular Type of Age-Related Macular Degeneration 6
Exudative Senile Macular Degeneration of Retina 12
Exudative Age-Related Macular Degeneration 73
Wet Senile Macular Retinal Degeneration 12
Senile Macular Degeneration, Wet 12
Exudative Macular Degeneration 73

Classifications:



External Ids:

Disease Ontology 12 DOID:10873
ICD10 33 H35.32
ICD9CM 35 362.52
SNOMED-CT 68 11290001 16018000

Summaries for Kuhnt-Junius Degeneration

MalaCards based summary : Kuhnt-Junius Degeneration, also known as neovascular age-related macular degeneration, is related to yemenite deaf-blind hypopigmentation syndrome and central serous chorioretinopathy. An important gene associated with Kuhnt-Junius Degeneration is HTRA1 (HtrA Serine Peptidase 1), and among its related pathways/superpathways are VEGF Pathway (Qiagen) and Signaling events mediated by VEGFR1 and VEGFR2. The drugs Ranibizumab and Verteporfin have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and retina, and related phenotype is vision/eye.

Related Diseases for Kuhnt-Junius Degeneration

Diseases related to Kuhnt-Junius Degeneration via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 50)
# Related Disease Score Top Affiliating Genes
1 yemenite deaf-blind hypopigmentation syndrome 30.8 CFH VEGFA
2 central serous chorioretinopathy 30.8 CFH ARMS2
3 retinal vascular disease 30.2 PGF VEGFA
4 macular degeneration, age-related, 1 28.8 VEGFB VEGFA SKIV2L SHROOM3 PGF HTRA1
5 macular degeneration, age-related, 12 10.6
6 cataract 10.5
7 macular retinal edema 10.4
8 macular holes 10.4
9 diabetic macular edema 10.4
10 charles bonnet syndrome 10.4
11 vitreous detachment 10.3
12 degos 'en cocarde' erythrokeratoderma 10.3
13 neovascular glaucoma 10.1 PGF VEGFA
14 epithelioid hemangioendothelioma 10.1 PGF VEGFA
15 macular dystrophy, dominant cystoid 10.1
16 parkinson disease, late-onset 10.1
17 pseudoxanthoma elasticum 10.1
18 coronary heart disease 1 10.1
19 neuropathy, hereditary, with or without age-related macular degeneration 10.1
20 microvascular complications of diabetes 5 10.1
21 hemorrhage, intracerebral 10.1
22 pemphigus foliaceus 10.1
23 open-angle glaucoma 10.1
24 heart disease 10.1
25 dementia 10.1
26 vascular disease 10.1
27 impotence 10.1
28 endophthalmitis 10.1
29 herpes zoster 10.1
30 psoriasis 10.1
31 ocular hypertension 10.1
32 herpes zoster ophthalmicus 10.1
33 macular telangiectasia type 2 10.1
34 depression 10.1
35 cancer-associated retinopathy 10.1 PGF VEGFA
36 retinal vascular occlusion 10.1 PGF VEGFA
37 dense deposit disease 10.1 CFB CFH
38 limb ischemia 10.1 PGF VEGFA
39 ectopic pregnancy 10.1 PGF VEGFA
40 enterocolitis 10.1 CFB CFH
41 autosomal genetic disease 10.0 VEGFA CFH ARMS2
42 placental insufficiency 10.0 PGF VEGFA
43 membranoproliferative glomerulonephritis 10.0 CFB CFH
44 retinal drusen 10.0 CFH CFB ARMS2
45 retinal disease 10.0 CFH CFB ARMS2
46 severe pre-eclampsia 9.9 PGF VEGFA
47 multifocal choroiditis 9.9 HTRA1 CFH CFB ARMS2
48 choroiditis 9.9 HTRA1 CFH CFB ARMS2
49 hemolytic uremic syndrome, atypical 1 9.9 CFHR4 CFH CFB
50 degeneration of macula and posterior pole 9.6 VEGFA SKIV2L HTRA1 CFH CFB ARMS2

Graphical network of the top 20 diseases related to Kuhnt-Junius Degeneration:



Diseases related to Kuhnt-Junius Degeneration

Symptoms & Phenotypes for Kuhnt-Junius Degeneration

MGI Mouse Phenotypes related to Kuhnt-Junius Degeneration:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 vision/eye MP:0005391 9.1 CFH HTRA1 PGF VEGFA VEGFB VLDLR

Drugs & Therapeutics for Kuhnt-Junius Degeneration

Drugs for Kuhnt-Junius Degeneration (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 161)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 347396-82-1 459903
2
Verteporfin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 129497-78-5
3
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
4
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
5
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
6
Lactitol Investigational Phase 4,Not Applicable 585-86-4 3871
7 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
8 Immunoglobulins Phase 4,Phase 2,Phase 1
9 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Antibodies, Monoclonal Phase 4,Phase 2,Phase 1
11 Antibodies Phase 4,Phase 2,Phase 1
12 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
13 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Photosensitizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Endothelial Growth Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Mitogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Autoantibodies Phase 4
19 Ketorolac Tromethamine Phase 4
20 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1,Not Applicable
21 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Not Applicable
22 Cyclooxygenase Inhibitors Phase 4
23 Ophthalmic Solutions Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
24 Analgesics Phase 4,Phase 2,Not Applicable
25 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Analgesics, Non-Narcotic Phase 4,Phase 2,Not Applicable
27 Antirheumatic Agents Phase 4,Phase 2,Phase 1,Not Applicable
28 Omega 3 Fatty Acid Phase 4,Not Applicable
29 Pyranoprofen Phase 4,Not Applicable
30 Tocolytic Agents Phase 4
31
Triamcinolone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 124-94-7 31307
32
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2 50-23-7 5754
33
Hydrocortisone acetate Approved, Vet_approved Phase 3,Phase 2 50-03-3
34
Dorzolamide Approved Phase 2, Phase 3 120279-96-1 5284549 3154
35
Timolol Approved Phase 2, Phase 3 26839-75-8 33624 5478
36
Povidone-iodine Approved Phase 3 25655-41-8
37
Povidone Approved Phase 3 9003-39-8
38
Iodine Approved, Investigational Phase 3 7553-56-2 807
39
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
40 Anecortave Investigational Phase 3,Phase 2,Phase 1 10184-70-0
41
Squalamine Investigational Phase 3,Phase 2 148717-90-2
42 Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
43 Triamcinolone diacetate Phase 3,Phase 2,Phase 1,Not Applicable
44 triamcinolone acetonide Phase 3,Phase 2,Phase 1,Not Applicable
45 glucocorticoids Phase 3,Phase 2,Phase 1,Not Applicable
46 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
47 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
48 Hormones Phase 3,Phase 2,Phase 1,Not Applicable
49 Triamcinolone hexacetonide Phase 3,Phase 2,Phase 1,Not Applicable
50 Fibrinolytic Agents Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 323)
# Name Status NCT ID Phase Drugs
1 Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration. Unknown status NCT01918878 Phase 4 Aflibercept (EYLEA)
2 Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD Unknown status NCT02810808 Phase 4 Ranibizumab
3 Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration Unknown status NCT00813891 Phase 4 Ranibizumab;Ranibizumab;Ranibizumab
4 Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD Unknown status NCT01213667 Phase 4 Ranibizumab
5 Treat and Extend Therapy Study Using Intravitreal Aflibercept for Patients Exited From Protocol VGFT-OD 0910 Unknown status NCT01961414 Phase 4 Aflibercept
6 On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD) Unknown status NCT01670162 Phase 4 Aflibercept
7 A Study Comparing Efficacy and Safety of "Treat-and-Extend" Regimen Versus PRN of Conbercept in AMD Unknown status NCT02802657 Phase 4 Conbercept
8 A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD Unknown status NCT00354445 Phase 4 pegaptanib sodium (Macugen)
9 Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy Unknown status NCT02976194 Phase 4 ranibizumab
10 EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection Unknown status NCT02689518 Phase 4 Intravitreal aflibercept injection
11 FUSION Regimen: Combined Pro re Nata and Fixed Regimen Ranibizumab in Exudative Age-related Macular Degeneration Completed NCT01500915 Phase 4 Ranibizumab
12 UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD) Completed NCT01988662 Phase 4
13 Functional and Structural Outcomes in Neovascular Age-related Macular Degeneration Completed NCT02843490 Phase 4 Ranibizumab
14 Intravitreal Aflibercept for Submacular Hemorrhage Completed NCT03169660 Phase 4 Vascular endothelial growth factor trap-eye
15 Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab Completed NCT02309281 Phase 4 aflibercept 2mg
16 Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept Completed NCT02125864 Phase 4 Aflibercept
17 Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Responders to Anti-Vascular Endothelial Growth Factor Completed NCT01896284 Phase 4 0.5mg aflibercept
18 Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®)START Completed NCT02246829 Phase 4
19 Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD) Completed NCT01863199 Phase 4 Lucentis (Treat and extend);Lucentis every 4 weeks;Lucentis every 12 weeks
20 Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD Completed NCT02161575 Phase 4 Ranibizumab
21 Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration) Completed NCT01775124 Phase 4 Ranibizumab
22 Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration Completed NCT02944227 Phase 4 Lucentis
23 Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration Completed NCT02060604 Phase 4 Ketorolac + Ranibizumab;Ranibizumab
24 Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration Completed NCT02305238 Phase 4 Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
25 LUCAS (Lucentis Compared to Avastin Study) Completed NCT01127360 Phase 4 Bevacizumab;Ranibizumab
26 Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection) Completed NCT01722045 Phase 4 Intravitreal Aflibercept Injection (IAI)
27 Single or Combined Protocols for NV-AMD Completed NCT03552770 Phase 4 Bevacizumab
28 Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab Completed NCT01810042 Phase 4 ranibizumab
29 PDT Study for Exudative AMD With PCV Completed NCT00331435 Phase 4
30 Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions Completed NCT00324116 Phase 4 pegaptanib sodium (Macugen)
31 Eylea to Treat Retinal Pigment Epithelial Detachment (RPED) Secondary to Wet Age-Related Macular Degeneration (wAMD) Completed NCT02142296 Phase 4 Eylea
32 Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration Completed NCT02257632 Phase 4 Ranibizumab;Aflibercept
33 Treatment of CNV With Aflibercept Combined With Pranoprofen Eye Drops or Nutraceutical Support With Omega-3 Completed NCT03355638 Phase 4 Aflibercept Injection [Eylea];Pranoprofen Eyedrops;Omega-3 Supplementation
34 Ranibizumab Plus Indomethacin Completed NCT03261635 Phase 4 Ranibizumab Injection;Indomethacin
35 Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept Completed NCT01617148 Phase 4 Aflibercept
36 Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy Completed NCT01950741 Phase 4 aflibercept
37 Study EvAluating Genotypes While Using Lucentis 2 Completed NCT01464723 Phase 4 Ranibizumab
38 Head to Head Study of Anti-VEGF Treatment. Completed NCT02577107 Phase 4 ranibizumab;Conbercept
39 Study for Recalcitrant Age Related Macular Degeneration Completed NCT01543568 Phase 4 aflibercept 2.0 mg
40 Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration Completed NCT00473642 Phase 4 Ranibizumab;Verteporfin;Verteporfin
41 Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD. Recruiting NCT02321839 Phase 4 Intraviteal Ranibizumab 0.5mg
42 Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye Active, not recruiting NCT02581891 Phase 4 Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321);Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)
43 PRedictive Factors and Changes From Treatment in iPCV Versus CSR Versus nAMD With afLibercept Not yet recruiting NCT02681783 Phase 4 aflibercept
44 Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept Not yet recruiting NCT03468296 Phase 4 Intravitreal Aflibercept Injection 2mg
45 Cytokine and Visual Outcome Variations in Eyes Receiving Ranibizumab Not yet recruiting NCT03056092 Phase 4 Intravitreal ranibizumab
46 Cytokine and Visual Outcome Variations in Eyes Receiving Aflibercept Not yet recruiting NCT03056079 Phase 4 Intravitreal aflibercept
47 An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD Terminated NCT00327470 Phase 4 Pegaptanib Sodium 0.3 mg
48 A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD) Terminated NCT00312351 Phase 4 Pegaptanib sodium
49 Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD) Terminated NCT00134667 Phase 4 Photodynamic Therapy (PDT) with Visudyne (verteporfin);Macugen (pegaptanib sodium)
50 TF (SENSIMED Triggerfish) in Intraocular Anti-VEGF (Vascular Endothelial Growth Factor) Injection Terminated NCT01983579 Phase 4

Search NIH Clinical Center for Kuhnt-Junius Degeneration

Genetic Tests for Kuhnt-Junius Degeneration

Anatomical Context for Kuhnt-Junius Degeneration

MalaCards organs/tissues related to Kuhnt-Junius Degeneration:

41
Eye, Endothelial, Retina, Testes, Bone, Bone Marrow, Whole Blood

Publications for Kuhnt-Junius Degeneration

Articles related to Kuhnt-Junius Degeneration:

(show top 50) (show all 1059)
# Title Authors Year
1
MACULAR ATROPHY INCIDENCE IN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Risk Factor Evaluation for Individualized Treatment Need of Ranibizumab or Aflibercept According to an Observe-and-Plan Regimen. ( 29370035 )
2018
2
OCT Angiography Helps Distinguish Between Proliferative Macular Telangiectasia Type 2 and Neovascular Age-Related Macular Degeneration. ( 29772040 )
2018
3
Outcomes and Predictive Factors After Cataract Surgery in Patients With Neovascular Age-related Macular Degeneration. The Fight Retinal Blindness! Project. ( 29550186 )
2018
4
QUANTITATIVE OPTICAL COHERENCE TOMOGRAPHY ANALYSIS OF RETINAL DEGENERATIVE CHANGES IN DIABETIC MACULAR EDEMA AND NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. ( 28492427 )
2018
5
Increased risk of neovascular age-related macular degeneration in patients with herpes zoster ophthalmicus: a retrospective cohort study. ( 30218493 )
2018
6
The role of posterior vitreous detachment on the efficacy of anti-vascular endothelial growth factor intravitreal injection for treatment of neovascular age-related macular degeneration. ( 30451182 )
2018
7
Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 Phoenix Study. ( 30401482 )
2018
8
Real-World Outcomes of Anti-VEGF Treatment for Neovascular Age-Related Macular Degeneration in Turkey: A Multicenter Retrospective Study, Bosphorus Retina Study Group Report No: 1. ( 30405944 )
2018
9
Statement of the BVA, the DOG, and the RG on treatment of choroidal neovascularization in diseases other than neovascular age-related macular degeneration : Dated Ocotber 2017. ( 30406470 )
2018
10
Radial shape discrimination testing for new-onset neovascular age-related macular degeneration in at-risk eyes. ( 30408127 )
2018
11
Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Neovascular Age-Related Macular Degeneration. ( 30412448 )
2018
12
Efficacy Comparison of Intravitreal Anti-VEGF Therapy for Three Subtypes of Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis. ( 30425852 )
2018
13
The effect of ranibizumab and aflibercept treatment on the prevalence of outer retinal tubulation and its influence on retreatment in neovascular age-related macular degeneration. ( 30428856 )
2018
14
Comment on "Assessment of the long-term visual and anatomical outcomes of ranibizumab to treat neovascular age-related macular degeneration". ( 30450325 )
2018
15
Outer Retinal Tubulation and Neovascular Age-Related Macular Degeneration: A Review of the Pathogenesis and Clinical Implications. ( 30457646 )
2018
16
Clinical effectiveness of ranibizumab and conbercept for neovascular age-related macular degeneration: a meta-analysis. ( 30464394 )
2018
17
Myofibroblasts in macular fibrosis secondary to neovascular age-related macular degeneration - the potential sources and molecular cues for their recruitment and activation. ( 30473378 )
2018
18
Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 Phoenix Study. ( 30477751 )
2018
19
Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated With Ranibizumab Using a Treat and Extend Regimen: FLUID Study 24 Month Results. ( 30502372 )
2018
20
One-year effectiveness study of intravitreous bevacizumab in neovascular age-related macular degeneration: a population-based retrospective cohort study. ( 30502989 )
2018
21
Atrophy in Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report Number 15. ( 30506012 )
2018
22
Better visual outcome at 1 year with antivascular endothelial growth factor treatment according to treat-and-extend compared with pro re nata in eyes with neovascular age-related macular degeneration. ( 30511374 )
2018
23
Characterisation of poor visual outcomes of neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor agents. ( 30529685 )
2018
24
Effects of Smoking on Outcomes of Antivascular Endothelial Growth Factor Therapy in Patients with Neovascular Age-Related Macular Degeneration Smoking and Anti-VEGF Therapy in nAMD. ( 30538852 )
2018
25
Retinal metabolic and structural alterations in response to aflibercept treatment in neovascular age-related macular degeneration. ( 30549221 )
2018
26
DRUSEN SUBTYPES AND CHOROIDAL CHARACTERISTICS IN ASIAN EYES WITH TYPICAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. ( 30550531 )
2018
27
Risk of Parkinson's disease in patients with neovascular age-related macular degeneration. ( 30555972 )
2018
28
TWELVE-MONTH OUTCOMES OF INTRAVITREAL AFLIBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Fixed Versus As-needed Dosing. ( 30161093 )
2018
29
EFFICACY OF ADJUVANT TOPICAL DORZOLAMIDE-TIMOLOL IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. ( 30161096 )
2018
30
Two year outcome in treatment-naive patients with neovascular age-related macular degeneration (nAMD) using an individualized regimen of Aflibercept. ( 30166233 )
2018
31
Factors influencing macular atrophy growth rates in neovascular age-related macular degeneration treated with ranibizumab or aflibercept according to an observe-and-plan regimen. ( 30166328 )
2018
32
The Use of Vascular Endothelial Growth Factor Inhibitors and Complementary Treatment Options in Polypoidal Choroidal Vasculopathy: A Subtype of Neovascular Age-Related Macular Degeneration. ( 30177632 )
2018
33
Development and testing of a patient-derived questionnaire for treatment of neovascular age-related macular degeneration: dimensions of importance in treatment of neovascular age-related macular degeneration. ( 30198182 )
2018
34
Human Vascular Endothelial Growth Factor A165 Expression Induces the Mouse Model of Neovascular Age-Related Macular Degeneration. ( 30200369 )
2018
35
Effect of mitochondrial haplogroups on ranibizumab response in neovascular age-related macular degeneration patients: a pilot study. ( 30203451 )
2018
36
Choroidal blood flow after the first intravitreal ranibizumab injection in neovascular age-related macular degeneration patients. ( 30203609 )
2018
37
Long-Term Regular Use of Low-Dose Aspirin and Neovascular Age-Related Macular Degeneration: National Sample Cohort 2010-2015. ( 30240791 )
2018
38
Bevacizumab dosing every 2 weeks for neovascular age-related macular degeneration refractory to monthly dosing. ( 30269186 )
2018
39
Five-year outcomes of a personalized pro re nata treatment regimen with anti-vascular endothelial growth factor for neovascular age-related macular degeneration. ( 30281212 )
2018
40
Plasma markers of chronic low-grade inflammation in polypoidal choroidal vasculopathy and neovascular age-related macular degeneration. ( 30288946 )
2018
41
Quantitative optical coherence tomography angiography biomarkers for neovascular age-related macular degeneration in remission. ( 30300393 )
2018
42
Onset of Retinal Pigment Epithelium Atrophy Subsequent to Anti-VEGF Therapy in Patients with Neovascular Age-Related Macular Degeneration. ( 30304737 )
2018
43
Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment. ( 30310267 )
2018
44
Development of Submacular Hemorrhage in Neovascular Age-related Macular Degeneration: Influence on Visual Prognosis in a Clinical Setting. ( 30311458 )
2018
45
Achieving balance in the treatment and monitoring of neovascular age-related macular degeneration in the real world: lessons from the Netherlands cohort of the AURA study. ( 30318723 )
2018
46
The Carnitine Shuttle Pathway is Altered in Patients With Neovascular Age-Related Macular Degeneration. ( 30326066 )
2018
47
Quantitative Fundus Autofluorescence in Non-Neovascular Age-Related Macular Degeneration. ( 30339266 )
2018
48
The Developing Regorafenib Eye drops for neovascular Age-related Macular degeneration (DREAM) study: an open-label phase II trial. ( 30341774 )
2018
49
Re: Adrean et al.: Consistent long-term therapy of neovascular age-related macular degeneration managed by 50 or more anti-VEGF injections using a treat-extend-stop protocol (Ophthalmology. 2018;125:1047-1053). ( 30343939 )
2018
50
Anti-VEGF Neovascular Age-Related Macular Degeneration Treatment Adherence Requires Attention and Action. ( 30352113 )
2018

Variations for Kuhnt-Junius Degeneration

ClinVar genetic disease variations for Kuhnt-Junius Degeneration:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 HTRA1 NM_002775.4(HTRA1): c.-625G> A single nucleotide variant risk factor rs11200638 GRCh38 Chromosome 10, 122461028: 122461028
2 HTRA1 NM_002775.4(HTRA1): c.-625G> A single nucleotide variant risk factor rs11200638 GRCh37 Chromosome 10, 124220544: 124220544

Expression for Kuhnt-Junius Degeneration

Search GEO for disease gene expression data for Kuhnt-Junius Degeneration.

Pathways for Kuhnt-Junius Degeneration

GO Terms for Kuhnt-Junius Degeneration

Cellular components related to Kuhnt-Junius Degeneration according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 CFB CFH CFHR4 HTRA1 PGF VEGFA
2 extracellular space GO:0005615 9.17 CFB CFH HTRA1 PGF VEGFA VEGFB

Biological processes related to Kuhnt-Junius Degeneration according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 angiogenesis GO:0001525 9.71 PGF VEGFA VEGFB
2 positive regulation of protein phosphorylation GO:0001934 9.7 PGF VEGFA VEGFB
3 response to hypoxia GO:0001666 9.69 PGF VEGFA VEGFB
4 positive regulation of angiogenesis GO:0045766 9.67 PGF VEGFA VEGFB
5 regulation of complement activation GO:0030449 9.63 CFB CFH CFHR4
6 positive regulation of endothelial cell proliferation GO:0001938 9.61 PGF VEGFA VEGFB
7 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.58 PGF VEGFA VEGFB
8 positive chemotaxis GO:0050918 9.54 PGF VEGFA VEGFB
9 positive regulation of cell division GO:0051781 9.5 PGF VEGFA VEGFB
10 complement activation, alternative pathway GO:0006957 9.48 CFB CFH
11 sprouting angiogenesis GO:0002040 9.43 PGF VEGFA VEGFB
12 vascular endothelial growth factor signaling pathway GO:0038084 9.33 PGF VEGFA VEGFB
13 induction of positive chemotaxis GO:0050930 9.13 PGF VEGFA VEGFB
14 positive regulation of mast cell chemotaxis GO:0060754 8.8 PGF VEGFA VEGFB

Molecular functions related to Kuhnt-Junius Degeneration according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heparin binding GO:0008201 9.56 CFH PGF VEGFA VEGFB
2 growth factor activity GO:0008083 9.54 PGF VEGFA VEGFB
3 chemoattractant activity GO:0042056 9.33 PGF VEGFA VEGFB
4 vascular endothelial growth factor receptor 2 binding GO:0043184 9.32 VEGFA VEGFB
5 vascular endothelial growth factor receptor 1 binding GO:0043183 8.96 VEGFA VEGFB
6 vascular endothelial growth factor receptor 3 binding GO:0043185 8.8 PGF VEGFA VEGFB

Sources for Kuhnt-Junius Degeneration

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....